1. Home
  2. IMXI vs OMER Comparison

IMXI vs OMER Comparison

Compare IMXI & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMXI
  • OMER
  • Stock Information
  • Founded
  • IMXI 1994
  • OMER 1994
  • Country
  • IMXI United States
  • OMER United States
  • Employees
  • IMXI N/A
  • OMER N/A
  • Industry
  • IMXI Retail: Computer Software & Peripheral Equipment
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMXI Technology
  • OMER Health Care
  • Exchange
  • IMXI Nasdaq
  • OMER Nasdaq
  • Market Cap
  • IMXI 619.2M
  • OMER 530.2M
  • IPO Year
  • IMXI N/A
  • OMER 2009
  • Fundamental
  • Price
  • IMXI $18.91
  • OMER $9.13
  • Analyst Decision
  • IMXI Buy
  • OMER Buy
  • Analyst Count
  • IMXI 6
  • OMER 4
  • Target Price
  • IMXI $27.50
  • OMER $22.50
  • AVG Volume (30 Days)
  • IMXI 146.1K
  • OMER 509.4K
  • Earning Date
  • IMXI 02-25-2025
  • OMER 03-31-2025
  • Dividend Yield
  • IMXI N/A
  • OMER N/A
  • EPS Growth
  • IMXI 21.49
  • OMER N/A
  • EPS
  • IMXI 1.80
  • OMER N/A
  • Revenue
  • IMXI $665,673,000.00
  • OMER N/A
  • Revenue This Year
  • IMXI $2.65
  • OMER N/A
  • Revenue Next Year
  • IMXI $2.82
  • OMER N/A
  • P/E Ratio
  • IMXI $10.53
  • OMER N/A
  • Revenue Growth
  • IMXI 3.79
  • OMER N/A
  • 52 Week Low
  • IMXI $16.17
  • OMER $2.61
  • 52 Week High
  • IMXI $23.28
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • IMXI 34.23
  • OMER 50.45
  • Support Level
  • IMXI $18.39
  • OMER $8.28
  • Resistance Level
  • IMXI $19.86
  • OMER $9.08
  • Average True Range (ATR)
  • IMXI 0.51
  • OMER 0.58
  • MACD
  • IMXI -0.14
  • OMER -0.05
  • Stochastic Oscillator
  • IMXI 17.25
  • OMER 62.58

About IMXI International Money Express Inc.

International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: